{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=23",
    "query": {
      "intervention": "nivolumab",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T15:25:42.670Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02275533",
      "title": "Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2015-07-02",
      "completion_date": "2026-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275533"
    },
    {
      "nct_id": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1096,
      "start_date": "2014-10-16",
      "completion_date": "2025-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 37,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231749"
    },
    {
      "nct_id": "NCT02518958",
      "title": "A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "RRx-001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpicentRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-07-21",
      "completion_date": "2016-09-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518958"
    },
    {
      "nct_id": "NCT03693014",
      "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Melanoma Cancer",
        "Lung Cancer",
        "Bladder Cancer",
        "Renal Cancer",
        "Head/Neck Cancers"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2018-10-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 10,
      "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693014"
    },
    {
      "nct_id": "NCT03970252",
      "title": "Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Borderline Resectable Pancreatic Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-07-24",
      "completion_date": "2024-05-25",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970252"
    },
    {
      "nct_id": "NCT02693535",
      "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Multiple Myeloma",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Sunitinib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Olaparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib plus Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Society of Clinical Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 4200,
      "start_date": "2016-03-14",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 174,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02693535"
    },
    {
      "nct_id": "NCT03386838",
      "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-03-28",
      "completion_date": "2018-04-19",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386838"
    },
    {
      "nct_id": "NCT01716806",
      "title": "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Peripheral T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2012-10-31",
      "completion_date": "2023-09-12",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716806"
    },
    {
      "nct_id": "NCT02595918",
      "title": "Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Stage I Renal Cell Cancer AJCC v6 and v7",
        "Stage II Renal Cell Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Metastasectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nephrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2016-05-19",
      "completion_date": "2020-08-01",
      "has_results": false,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595918"
    },
    {
      "nct_id": "NCT04100018",
      "title": "A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1030,
      "start_date": "2020-02-06",
      "completion_date": "2024-06-25",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-10-24T15:25:42.670Z",
      "location_count": 45,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 41 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04100018"
    }
  ]
}